Dario Graceffa, Arianna Zangrilli, Giacomo Caldarola, Viviana Lora, Diego Orsini, Gala Moretta, Gianluca Pagnanelli, Alessia Provini, Cinzia Masini, Mauro Bavetta, Domenico Giordano, Antonio Richetta, Ersilla Tolino, Luca Bianchi, Ketty Peris, Francesca Sperati, Claudio Bonifati
BACKGROUND: IL-23 inhibitors were recently approved for the treatment of skin psoriasis and psoriatic arthritis (PsA). Risankizumab, a humanized monoclonal antibody that specifically binds the p19 subunit of IL-23, has proven effective on PsA in two randomized controlled trials. To date, only a few real-world data are available on this topic. METHODS: Our study aimed to prospectively evaluate the effectiveness of risankizumab in patients with PsA in a real-world setting...
April 7, 2024: International Journal of Dermatology